Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (at randomisation):~1. Competent to provide written informed consent~2. 35-70 years old~3. Body Mass Index (BMI) 19 to 33 kg/m2~4. Mild to moderate hypertension per British Hypertension Society (BHS) Guidelines BHS-IV based on the following criteria of sitting blood pressure for subjects without diabetes or renal dysfunction.~5. Average sitting morning DBP 90 to 109 mmHg and SBP 140 to 179 mmHg and have responded positively to a quinapril challenge.~Principal exclusion criteria:~1. Women of childbearing potential: defined to be not surgically sterile and \<2 y post-menopausal~2. Average sitting SBP of \>180 mmHg or DBP of \>110 mmHg.~3. A BP difference between left and right arm greater than 20 mmHg for SBP and 10 mmHg for DBP which is present on 3 consecutive readings.~4. Left ventricular (LV) systolic dysfunction as evidenced by a known LV ejection fraction \<40% or symptomatic congestive heart failure requiring treatment.~5. HbA1c \>7.0% or a history of Type 1 or Type 2 diabetes.~6. Haemoglobin \<12 g/dL at Screening.~7. Hypo- or hyperthyroidism~8. Serum alanine aminotransferase or aspartate aminotransferase \>2X ULN.~9. Other identifiable secondary causes of hypertension~10. Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of Screening.~11. Bradycardia \<50 beats per minute at rest in the supine position prior to randomisation.~12. Have sick sinus syndrome or second or third degree atrioventricular block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia (including paroxysmal atrial tachycardia), history of recurrent ventricular tachycardia, or symptomatic bradycardia.~13. Implanted pacemakers or cardioverter defibrillator.~14. Haemodynamically significant valvular heart disease.~15. History of renal dysfunction and/or estimated glomerular filtration rate \<60 mL/min/1.73 m2.~16. Diagnosis or recurrence of malignancy within the past 3 years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix.~17. Sleep apnea unless a recent (within 30 days of Screening) sleep study demonstrates no recordings of arterial oxygen saturation (SaO2) \<90%, treated or untreated, at any time during the Screening Period.~18. Perform alternating shift or night work.~19. Not on stable doses of all concomitant medications for a minimum of 4 weeks prior to Screening, and subjects treated with any of the following prohibited medications:~    * Oral corticosteroids within 3 months of Screening.~   * Acetylsalicylic acid in excess of 325 mg per day.~   * Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid is prohibited.~   * Selective serotonin reuptake inhibitors or selective serotonin norepinephrine reuptake inhibitors, if a subject is not compliant with the medication and/or has not been receiving a stable dose for at least 3 months prior to Screening.~   * Tricyclic antidepressants, if a subject is not compliant with the medication and/or has not been receiving a stable dose for at least 3 months prior to Screening.~   * Any angiotensin vaccine, including prior exposure to ATV.~20. Have participated in a clinical study involving another investigational drug or device within 4 weeks of Screening.~21. Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit the subject's ability to complete the study (eg, disabling or terminal illness, mental disorders).~22. Any major contraindication to stopping antihypertension medications for a period of up to 14 weeks.~23. Previous exposure to CoVaccine HT adjuvant, or other keyhole limpet haemocyanin-containing vaccines.~24. Previous serious reaction to a vaccine, such as angioedema or anaphylaxis.~25. Known history of drug and/or alcohol abuse and those known to be hepatitis positive.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ATV with CoVaccine HT™ (Type: EXPERIMENTAL): Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
- CoVaccine HT™ adjuvant alone (Type: PLACEBO_COMPARATOR): CoVaccine HT™ adjuvant alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues